Travere Therapeutics - M&A Summary and Business Overview

Life ScienceCompany

Travere Therapeutics M&A Summary

Travere Therapeutics has acquired 3 companies.

Travere Therapeutics’ largest acquisition to date was in 2014, when it acquired Manchester Pharmaceuticals for $63M. Travere Therapeutics has acquired in 3 different US states. The Company’s most targeted sectors include life science (100%).

Travere Therapeutics Business Overview

Where is Travere Therapeutics headquartered?

Travere Therapeutics is headquartered in San Diego, California.

What is Travere Therapeutics’ revenue?

Travere Therapeutics disclosed revenue of 145M USD for 2023 and 109M USD for 2022.

How many employees does Travere Therapeutics have?

Travere Therapeutics has 380 employees.

What sector is Travere Therapeutics in?

Travere Therapeutics is a life science company.

When was Travere Therapeutics founded?

Travere Therapeutics was founded in 2011.

M&A Summary

  • M&A Total Activity3
    • M&A Buy Activity3
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 1

Travere Therapeutics

Travere Therapeutics, Inc.

3611 Valley Centre Drive Suite 300,
San Diego, California 92130
United States,
(888) 969-7879
www.travere.com

Travere Therapeutics is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Travere Therapeutics was founded in 2011 and is based in San Diego, California.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 3 - - - - - 3
vol $63M $63M
Sell (0.0/yr) # - - - - - - 0
  3

Most Recent M&A

Company Date Value Type
Asklepion - Liquid Formulation Of Ursodeoxycholic Acid 2016-06-20 - Divestiture
, United States
Manchester Pharmaceuticals, Inc. 2014-02-12 63M USD Add-on Acquisition
Fort Collins, Colorado · www.manchesterpharma.com
Kyalin Biosciences, Inc. 2013-12-12 - Add-on Acquisition
Encinitas, California · www.kyalinbio.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 3 (100%) 63M (100%) - -
Total 3 $63M - -

By Geo

State/Country Buy Value Sell Value
United States 3 63M - -
  Colorado 1 63M - -
  California 1 - - -
Total 3 $63M - -

Deal Values

buy # Total
< $100M 1 $63M
TOTAL $63M
Largest Manchester Pharmaceuticals, Inc.
$63M (2014-02-12)

M&A Connections

Deals
Acquired from
Strategic(s)
33%
1 (33%)

 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.